Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Moodys
Chinese Patent Office
Daiichi Sankyo
UBS
US Department of Justice
Merck
McKesson
Healthtrust

Generated: February 18, 2019

DrugPatentWatch Database Preview

Perrigo New York Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO NEW YORK, and when can generic versions of PERRIGO NEW YORK drugs launch?

PERRIGO NEW YORK has fifty-eight approved drugs.

There is one US patent protecting PERRIGO NEW YORK drugs.

There are five patent family members on PERRIGO NEW YORK drugs in five countries and eighteen supplementary protection certificates in nine countries.

Summary for Perrigo New York
International Patents:5
US Patents:1
Tradenames:30
Ingredients:29
NDAs:58
Patent Litigation for Perrigo New York: See patent lawsuits for Perrigo New York

Drugs and US Patents for Perrigo New York

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo New York NYSTATIN nystatin OINTMENT;TOPICAL 062472-001 Feb 13, 1984 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Perrigo New York PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride SUPPOSITORY;RECTAL 040500-001 Jun 30, 2003 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Perrigo New York PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride SUPPOSITORY;RECTAL 040500-002 Jun 30, 2003 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Perrigo New York Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
C/GB02/033 United Kingdom ➤ Try a Free Trial PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Colorcon
Argus Health
Farmers Insurance
Fish and Richardson
Moodys
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.